AstraZeneca Faces 'Key Pressures' But $45bn Sales Target 'Still Achievable'
This article was originally published in Scrip
Executive Summary
AstraZeneca's business is under two key pressures as it enters 2016, CEO Pascal Soriot explained during the company's fourth quarter and full year 2015 presentation: the "enormous headwinds" created by the US patent expiry of Crestor this year and the dilutive effect of the ZS Pharma and Acerta Pharma acquisitions. AstraZeneca reported fourth quarter and full-year numbers broadly in-line with expectations, meeting guidance for 2015.
You may also be interested in...
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
The first round of biopharma earnings presentations reflects concerns about pricing and market access, which should carry over as big pharma stalwarts come center stage.
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
AstraZeneca's first-half results presentation highlighted its growing early pipeline, notably in oncology, but also the increasing pain of generic erosion on its Crestor sales – underlining again the importance new drugs will play in the group's turnaround strategy.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.